Compare AAP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | TLX |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2002 | N/A |
| Metric | AAP | TLX |
|---|---|---|
| Price | $53.15 | $11.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $53.50 | $21.13 |
| AVG Volume (30 Days) | ★ 1.7M | 181.0K |
| Earning Date | 05-21-2026 | 08-19-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 113.01 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $8,601,000,000.00 | N/A |
| Revenue This Year | $0.35 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | ★ $142.08 | $150.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.89 | $6.28 |
| 52 Week High | $70.00 | $16.85 |
| Indicator | AAP | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 56.19 |
| Support Level | $47.54 | $9.42 |
| Resistance Level | $53.82 | $11.38 |
| Average True Range (ATR) | 2.73 | 0.25 |
| MACD | -0.73 | -0.06 |
| Stochastic Oscillator | 3.34 | 39.17 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.